Physician profile
Lav Kapadia
NPI 1437153418
$2,680.97
in general payments reported to CMS, 2019-2025
23 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $286 · 2021: $232 · 2022: $220 · 2023: $336 · 2024: $344 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.68 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $691.36 | 2019-2025 | Scopis Ent, Clarifix |
| Acclarent, INC | $459.33 | 2019-2024 | Trudi Nav Cable, Acclarent Aera |
| Medtronic, INC. | $336.11 | 2024-2025 | Propel, Ligasure |
| Inspire Medical Systems, INC. | $204.80 | 2023-2025 | Inspire |
| Aerin Medical INC. | $150.81 | 2019-2024 | |
| Integra Lifesciences Corporation | $101.32 | 2024-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Optinose US, INC. | $74.47 | 2019-2025 | |
| Intersect Ent, INC. | $67.79 | 2020-2021 | |
| Genzyme Corporation | $67.71 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $61.88 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $56.36 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $48.42 | 2021-2025 | Nucala |
| Itamar Medical INC | $42.47 | 2023 | Watchpatone |
| Alk-Abello, INC | $40.97 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $37.04 | 2022 | |
| Aytu Biopharma, INC. | $29.46 | 2024-2025 | Karbinal |
| Merck Sharp & Dohme LLC | $24.30 | 2023 | |
| Kerecis Limited | $21.39 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Livanova USA, INC. | $21.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.61 | 2022 | |
| Hikma Pharmaceuticals USA | $14.77 | 2023 | Ryaltris |
| Pfizer INC. | $14.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lav Kapadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.